** ASX-listed shares of medical device-maker ResMed RMD.AX fall as much as 7.3% to A$36.02, their lowest level since April 24
** Stock of co, which is involved in treating sleep apnea, COPD and other chronic diseases, marks biggest intraday pct loss since March 12
** RMD is the top pct loser on the ASX 200 benchmark
** Rival Apnimed, which is unlisted, announced positive topline results in first phase 3 clinical trial of AD109, an oral pill for obstructive sleep apnea
** Stock up 0.6% YTD
(Reporting by Sneha Kumar in Bengaluru)
((Sneha.kumar@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.